Biocept to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies

SAN DIEGO--(BUSINESS WIRE)--

Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its senior scientists, Farideh Bischoff, Ph.D., Vice President of Translational Research, and Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer, will be making presentations at the 19th Annual Molecular Medicine Tri-Con being held in San Francisco February 19-23.

Dr. Arnold spoke during the “Blood-Based Cancer Diagnostics” session on Monday, February 20th. His talk, entitled “The Capture, Identification and Interrogation of Circulating Tumor Cells,” touched on a proprietary, highly sensitive mutation detection technology developed at Biocept called “SelectorTM.” Dr. Bischoff will speak during the “Clinical Use of Circulating Tumor Cells” session on Wednesday, February 22nd. Her talk, entitled “Capture and Detection of CK+ and CK- CTCs for Subsequent Molecular Analysis Using the OncoCEETM Platform,” will cover in part a continuing clinical study in breast cancer with collaborators at the MD Anderson Cancer Center.

Biocept’s first test, OncoCEE-BRTM for breast cancer, is available through its commercialization partner Clarient, Inc., a GE Healthcare Company. The test includes CTC enumeration and determination of HER2 status by fluorescence in situ hybridization (FISH) from a blood sample. Determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunocytochemical staining will be added to the test later this year. OncoCEE-BR is the first commercially available CTC test to include analysis of a specific, treatment-associated biomarker (HER2).

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, California, is an advanced laboratory services company specializing in the capture, isolation, detection and analysis of Circulating Tumor Cells (CTCs). Biocept’s mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes patented and innovative technologies to deliver clinically relevant and actionable information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with important information for the treatment of their patients with cancer.

Originally posted here:
Biocept to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies